Quince Therapeutics, Inc. (QNCX)
Develops a therapy that puts medicine inside patients' own blood cells to treat rare neurological diseases.
$22.00+0.14%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-93.5%
The outlook
QNCX is trading near its 52-week low with mixed momentum against its moving averages. Analyst sentiment leans bearish overall, though the average price target sits substantially above the current price at around +279%. The wide gap between current valuation and analyst targets reflects significant disagreement in the market.
What’s behind the score
Price trendMixed vs its moving averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +279% vs current price
Analyst price target
~12-month · 3 analysts$83.33average target+278.8% vs now
Now $22.00
Low $70.00High $100.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$21.5M
52-wk high
$910.00
52-wk low
$15.10
50-day avg
$19.45
200-day avg
$220.52
Trailing P/E
—